April Martinez-Dulay, MSN, APRN, FNP-C, is a Consultative Complex Medical Dermatology Nurse Practitioner at the Palo Alto Medical Foundation (PAMF).

April Martinez-Dulay, MSN, APRN, FNP-C

April Martinez-Dulay, MSN, APRN, FNP-C—known for her work as a Consultative Complex Medical Dermatology Nurse Practitioner at the Palo Alto Medical Foundation (PAMF)—spoke with 

Dermatology Education Foundation (DERM) 2025 NP/PA CME Conference

 in Las Vegas about a topic highlighted in one of her sessions: allergic contact dermatitis.

Martinez-Dulay noted allergic contact dermatitis commonly impacts the eyelids, face, hands, perianal, and genital areas, with 22-45% prevalence. A diagnosis of this type of reaction relies on patch testing in dermatology offices, distinguishing between immediate (15 minutes) and delayed (48 hours) hypersensitivity reactions.

Clinical Pearls on Managing Allergic Contact Dermatitis, with April Martinez-Dulay, MSN, APRN, FNP-C

“Patch testing is done in a dermatology office,” Martinez-Dulay said. “When you go to a website called ACDS, or Allergic Contact Dermatitis Society, you will be able to locate who the providers are who perform the patch testing. One of the most important things when you have allergic contact is allergen avoidance.”

The ACDS website helps locate providers and Martinez-Dulay suggests allergen avoidance. For example, if allergic to fragrance allergens like balsams, products are listed. Various treatments for atopic dermatitis were noted as available, including topical and oral medications, and biologics like IL-31, IL-13, and IL-4 for moderate to severe cases.

Later, Martinez-Dulay was asked about the research and recently-approved treatments about which she is most excited, relating her answer specifically to dermatologic diseases like atopic dermatitis.

“We have a lot of therapies that are available now for atopic dermatitis,” she explained. “We have come to use the topicals and oral medicines. And we have IL-31, we have IL-13, and IL-4 available. These are very effective and are available for our patients…if they have moderate to severe atopic dermatitis.”

To find out additional information on such subjects, view Martinez-Dulay’s full interview segment above. For more from DERM 2025, view the 

The quotes implemented in this interview summary were edited for clarity.

Martinez-Dulay, A. Targeting the IL-31 Neuroimmune Pathway: A Key to AD and Prurigo Nodularis. Presented at DERM 2025 NP PA CME Conference; July 23-26, 2025; Las Vegas, Nevada.

Martinez-Dulay, A. Surfing through the Diagnostic Maze of Dermatitis and Lymphoma. Presented at DERM 2025 NP PA CME Conference; July 23-26, 2025; Las Vegas, Nevada.

Videos

During this DERM 2025 interview segment, Martinez-Dulay touches on highlights from her sessions in which she explores allergic contact dermatitis.

 in Las Vegas, presenter April Martinez-Dulay, MSN, APRN, FNP-C, spoke with 

 about her session titled ‘Targeting the IL-31 Neuroimmune Pathway: A Key to AD and Prurigo Nodularis.’

Martinez-Dulay, who works as a Consultative Complex Medical Dermatology Nurse Practitioner at the Palo Alto Medical Foundation (PAMF), discussed the morphology-based condition prurigo nodularis and 

, emphasizing the importance of recognizing pruritus, eczema, and chronic relapsing symptoms.

Managing Atopic Dermatitis and Prurigo Nodularis, with April Martinez-Dulay, NP

“I gave a pearl about atopic dermatitis, providing 3 essential criteria of interpretation,” Martinez-Dulay said. “Number 1 is your pruritus. Number 2 is your eczema, and number 3 is the chronic, limiting, relapsing condition. And there are also important features with atopic dermatitis, including atopic eczema, cirrhosis, and dryness of skin. These are kind of important things for us to remember.”

Martinez-Dulay also discussed several points related to psoriasis, highlighting locations on which the condition is commonly found.

“In the textbook, we find them at the scalp, the elbows, the knees, and a very, very important area to look for is under the gluteal cleft,” Martinez-Dulay explained. “So you look at the pinking in the gluteal cleft, and that is psoriasis. For atopic dermatitis, when the patient tells you I feel like I'm allergic to my sweat, and that is her AD.”

Later, Martinez-Dulay discussed some of the topics highlighted in her talk titled ‘Surfing through the Diagnostic Maze of Dermatitis and Lymphoma,’ including a particular case that led her to the conclusion that a lack of responses to therapies should lead to a biopsy of a lesion.

 This may then lead to a diagnosis of lymphoma.

For any additional information on these topics, view the full interview segment above. To find out more from DERM 2025, view the 

The quotes used in this interview were edited for clarity.

In her DERM 2025 conference interview, Martinez-Dulay highlights takeaways from her sessions on atopic dermatitis, prurigo nodularis, and lymphoma.

April Martinez-Dulay, MSN, APRN, FNP-C

Articles